Boston Scientific (BSX) Fundamental Analysis: Revenue, Earnings & Valuation

8.30 / 10

Outperform

Fundamental analysis gives BSX an 8.3/10 score. Profit‑MV, Cash‑MV, ROA and profit margins rank in top quartiles, driving strong quality. Asset‑MV and Net‑profit/Total‑profit lag, but overall the company shows a very promising financial profile.

Analysis Checks(8/10)

ROA (%)

Value6.96

Score3/3

Weight10.81%

1M Return0.90%

Net cash flow from operating activities / Operating revenue (%)

Value22.59

Score3/3

Weight22.43%

1M Return1.78%

Profit-MV

Value0.22

Score2/3

Weight15.90%

1M Return1.31%

Net profit margin (%)

Value14.41

Score3/3

Weight9.93%

1M Return0.82%

Total profit / EBIT (%)

Value90.65

Score3/3

Weight18.71%

1M Return1.54%

Net cash flow from operating activities / Total liabilities (%)

Value0.24

Score3/3

Weight17.33%

1M Return1.42%

Annualized net profit margin on total assets (%)

Value6.96

Score3/3

Weight10.81%

1M Return0.90%

Asset-MV

Value-0.55

Score1/3

Weight-11.33%

1M Return-1.06%

Cash-MV

Value-0.46

Score2/3

Weight34.65%

1M Return2.64%

Net profit / Total profit (%)

Value85.44

Score1/3

Weight-29.24%

1M Return-3.12%

Is BSX fundamentally strong?

BSX scores 8.30/10 on fundamentals and holds a Discounted valuation at present. Backed by its 12.47% ROE, 14.41% net margin, 34.95 P/E ratio, 4.14 P/B ratio, and 55.56% earnings growth, these metrics solidify its Outperform investment rating.